About the Company
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University). The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. NTLA-2002 is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 1 / 2 studies. Intellia's proprietary non-viral gene knock out platform deploys lipid nanoparticles to deliver to the liver a two-part genome editing system: guide RNA specific to the disease-causing gene and messenger RNA that encodes the Cas9 enzyme, which carries out the precision editing. Intellia also has a number of research programs for in vivo and ex vivo therapeutic candidates with potential applications in diseases including cancer, alpha-1 antitrypsin deficiency, and hemophilia. The company is also working on a variety of additional gene editing technologies including base editing and DNA writing.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NTLA News
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
We expect investors to focus on Intellia Therapeutics, Inc.’s NTLA progress with the development of its portfolio of ...
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
With Bristol Myers’ latest cuts, biopharma layoffs reach 7,800+
After investing $24 billion in three major acquisitions earlier this year, Bristol Myers Squibb Co. said April 25 if would cut 2,200 employees and discontinue 12 programs in an effort to save $1.5 ...
Mammoth gets $95M from Regeneron in CRISPR/gene-editing deal
Seven years after embarking on in vivo therapeutic development using CRISPR/Cas gene-editing technology with Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc. is bringing another company into ...
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
Detailed price information for Teladoc Health Inc (TDOC-N) from The Globe and Mail including charting and trades.
Crispr Therapeutics: Now Is The Time To Buy
Despite recent FDA approvals for gene editing technology, CRISPR Therapeutics' stock declined. Click here to read an analysis of CRSP stock now.
CM Labs Adds Dynamic Fault Injection to Intellia Instructor
The new feature is designed to help operators solve challenges, hone their skills, understand equipment control and refine ...
3 Cathie Wood ETFs Just Hit 4-Month Lows. Are They Worth Buying Now?
Cathie Wood, a well-known fund manager who heads asset management company Ark Invest, is known for her ultra-aggressive ...
Enliven Therapeutics adds physician to board
Enliven Therapeutics Inc., a clinical-stage precision oncology company, has appointed physician Lori Kunkel to its board of ...
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
ARK Invest's 13F portfolio value decreased by 15% this quarter, with the number of holdings increasing from 223 to 230. Click ...
Generative AI for Healthcare: Xaira Therapeutics Launches with $1 Billion Funding
ARCH Venture Partners and Foresite Labs have invested $1 billion in AI-driven drug discovery firm Xaira Therapeutics, aiming ...
CAR T-Cell Therapy Market Analysis, Sales, Share and Research Depth Study 2031
The global CAR T-Cell Therapy Market is projected to reach more than USD 22.2 billion by 2032 from USD 2.1 billion in 2023, growing at a CAGR of 30% from 2024-2032.
Loading the latest forecasts...